A group of researchers chasing the theory that Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent or substandard regulations say they have evidence to bolster it.
In a working paper published on the website of the National Bureau of Economic Research, Roger Bate, Ginger Zhe Jin, Aparna Mathur and Amir Attaran have found that in a qualitative appraisal of 1,470 drugs claimed to be “made in India,” 10.9 per cent failed a basic assessment of active pharmaceutical ingredients. This pilot study seeks to focus on drugs that are labelled “made in India,” as these are among the most commonly used in developing countries. The samples that had the Indian label were from 14 unique manufacturers. But the authors remind us that the label “made in India” does not necessarily mean the actual manufacturer is an Indian firm.
“In a few instances, we obtained information that samples were faked by organised criminals in China,” they say.
